Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
To accelerate the development of next-generation radioconjugates to treat cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Comprehensive clinical development programs being initiated for each investigational candidate
Subscribe To Our Newsletter & Stay Updated
